Laboratory assessment of new anticoagulants

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Anticoagulation by factor Xa inhibitors

(2010) T. ORFEO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

(2010) Jean Amiral et al.   THROMBOSIS AND HAEMOSTASIS

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Monitoring Thrombin Generation by Electrochemistry: Development of an Amperometric Biosensor Screening Test for Plasma and Whole Blood

(2009) C. Thuerlemann et al.   CLINICAL CHEMISTRY

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

(2009) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Rap1b is critical for glycoprotein VI-mediated but not ADP receptor-mediated α2β1activation

(2009) Z. WANG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

(2009) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study

(2009) M. R. LASSEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Newer anticoagulants in 2009

(2009) Meyer Michel Samama et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

New oral anticoagulants in development

(2009) J. I. Weitz   THROMBOSIS AND HAEMOSTASIS

Prothrombinase-Induced Clotting Time Assay for Determination of the Anticoagulant Effects of Unfractionated and Low-Molecular-Weight Heparins, Fondaparinux, and Thrombin Inhibitors

(2008) Andreas Calatzis et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Thrombin generation testing in routine clinical practice: are we there yet?

(2008) J. J. van Veen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Treatment and Prevention of Heparin-Induced Thrombocytopenia

(2008) Theodore E. Warkentin et al.   CHEST

Prevention of Venous Thromboembolism

(2008) William H. Geerts et al.   CHEST

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

New anticoagulants

(2008) Kenneth A Bauer   CURRENT OPINION IN HEMATOLOGY

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients

(2008) Robert Siegmund et al.   THROMBOSIS RESEARCH

Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications

(2008) Sebastian Harder et al.   THROMBOSIS RESEARCH